BMO Raises USAS Target to C$12 on Galena Antimony Production

BMO Capital Markets raised its price target on Americas Gold and Silver Corporation (USAS) to C$12 from C$10 on May 19, keeping an Outperform rating. The firm said Galena Complex production is on track and highlighted the company's execution of its operational optimization plan. The new target implies roughly 20% upside from the stock's level before the upgrade.

During the Q1 FY2026 earnings call on May 15, management reported steady progress across its operations. Production growth and cost performance drove the quarter. The company also emphasized a strategic shift toward antimony. Galena is one of the few active domestic sources of antimony production in the United States, the company said. That matters because antimony is classified as a critical mineral by the U.S. government. Domestic supply is limited. China controls about 70% of global antimony production and has tightened export controls in recent years, pushing prices higher.

USAS has returned 285% over three years, outperforming the broader market by a wide margin. Quarterly revenue rose 188% year over year. The company, founded in 1998, develops gold, silver, zinc, lead, and other by-products from its properties in the Americas. The revenue growth reflects higher metals prices and the ramp at Galena, which resumed full operations in 2024 after a multi-year care-and-maintenance period.

The antimony angle adds a layer of strategic value beyond the base metals. Antimony is used in flame retardants and military applications such as night-vision goggles and ammunition. Few domestic sources exist. Galena's output gives USAS a unique position if demand or policy shifts favor U.S.-sourced material. BMO's upgrade explicitly cited the antimony opportunity.

Antimony prices have more than doubled since 2020. China's export quotas and defense stockpiling have driven the rally. The U.S. Department of Defense has identified antimony as a critical mineral for national security. Any policy that incentivizes domestic production would directly benefit Galena. BMO's upgrade reflects that potential.

Execution remains the key variable. Galena has a history of operational challenges, including ground conditions and permitting delays. The optimization plan is still in early stages. The Q1 results showed progress. Sustained production at target rates will determine whether the stock holds its gains. The company guided for higher production in the second half of the year. Any miss would test investor confidence. USAS trades on the NYSE American with average daily volume of about 500,000 shares, making it a small-cap name with corresponding liquidity risk.

The broader commodity backdrop supports the thesis. Silver prices are near multi-year highs. Gold is above $2,400 an ounce. Antimony prices have climbed because Chinese export restrictions have tightened. USAS offers leveraged exposure to all three metals through its Galena and other properties. That leverage works both ways: a pullback in metals prices would pressure the stock.

The next catalyst is the Q2 production report, due in August. If Galena continues to ramp and antimony prices hold, the BMO target could prove conservative. A miss on either front would test the stock's recent rally. For now, the market is pricing in the antimony opportunity. It is not fully discounting execution risk.